Additionally, GC patients with high GLI1/GLI2 and ABCG2 signatures were associated with a shorter overall survival (OS) and higher cancer relapse, suggesting that higher expressions of these genes predicted a poorer outcome in GC patients who underwent 5-FU and cisplatin-based chemotherapy. This evidence concerns the gene GLI1 and gastric cancer.